270 related articles for article (PubMed ID: 23197199)
1. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.
Yamashita T; Abbade LP; Marques ME; Marques SA
An Bras Dermatol; 2012; 87(6):817-28; quiz 829-30. PubMed ID: 23197199
[TBL] [Abstract][Full Text] [Related]
2. Lymph node histopathology in mycosis fungoides and Sézary's syndrome.
Scheffer E; Meijer CJ; Willemze R; van Vloten WA
Curr Probl Dermatol; 1990; 19():105-13. PubMed ID: 2404671
[No Abstract] [Full Text] [Related]
3. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
5. Mycosis fungoides and Sézary's syndrome show distinct histomorphological features.
Imai S; Burg G; Braun-Falco O
Dermatologica; 1986; 173(3):131-5. PubMed ID: 3770259
[TBL] [Abstract][Full Text] [Related]
6. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
7. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile.
Saed G; Fivenson DP; Naidu Y; Nickoloff BJ
J Invest Dermatol; 1994 Jul; 103(1):29-33. PubMed ID: 8027577
[TBL] [Abstract][Full Text] [Related]
8. Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.
Pulitzer MP; Horna P; Almeida J
Cytometry B Clin Cytom; 2021 Mar; 100(2):132-138. PubMed ID: 32516521
[TBL] [Abstract][Full Text] [Related]
9. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria.
Glusac EJ; Shapiro PE; McNiff JM
Dermatol Clin; 1999 Jul; 17(3):601-14, ix. PubMed ID: 10410861
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging.
Feng B; Jorgensen JL; Jones D; Chen SS; Hu Y; Medeiros LJ; Wang SA
Mod Pathol; 2010 Feb; 23(2):284-95. PubMed ID: 19935642
[TBL] [Abstract][Full Text] [Related]
13. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
14. New aspects of the clinicopathological features and treatment of mycosis fungoides and Sézary syndrome.
Furue M; Kadono T
J Dermatol; 2015 Oct; 42(10):941-4. PubMed ID: 26432429
[TBL] [Abstract][Full Text] [Related]
15. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
16. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
17. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
18. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome.
Shono Y; Suga H; Kamijo H; Fujii H; Oka T; Miyagaki T; Shishido-Takahashi N; Sugaya M; Sato S
Acta Derm Venereol; 2019 Jul; 99(9):809-812. PubMed ID: 31045236
[TBL] [Abstract][Full Text] [Related]
19. Sézary syndrome and mycosis fungoides flow cytometric evaluation: The clinicians' perspective.
Guitart J
Cytometry B Clin Cytom; 2021 Mar; 100(2):129-131. PubMed ID: 32017375
[TBL] [Abstract][Full Text] [Related]
20. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]